KF21213
目录号 : GC31217
KF21213高选择性地结合到腺苷A2A受体，Ki值为3.0nM。
Cas No.:155271-17-3
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Kinase experiment: | The in vitro affinity of KF21213 for the adenosine A2A and A1 receptors is determined using the rat striatal membrane and [3H]CGS 21680 as a radioligand and the rat forebrain membrane and N6-[3H]cyclohexyladenosine, respectively. The assay is performed in the dark to prevent photo-isomerization[1]. |
Cell experiment: | Mice[1]Two groups of male ddY mice (30-39 g) are used. In the first group, [11C]KF21213 (1.1 MBq/36 pmol) is intravenously injected. They are killed by cervical dislocation at 5, 15, 30, and 60 min after injection (N=4 each). Blood is collected by heart puncture. The brain is removed and dissected into the striatum, cortex, and cerebellum. The regional brain uptake of radioactivity is measured as the percentage of injected dose per gram tissue (%ID/g). In the other group, [11C]KF21213 (1.1 MBq/21 pmol) is co-injected with one of the following adenosine receptor antagonists: A2A antagonists KF21213, KF17837, KF18446, and SCH 58261 and an A1 antagonist KF15372. The injected dose of KF21213 is 30 nmol and that of other antagonists is 50 nmol. The mice are killed at 15 min after injection (N=9 for control and N=4 for each of the other groups). The regional brain uptake of radioactivity is measured. Rat[1]PET measurement is performed in three rats with a model SHR-2000 camera with Z=2 mode, providing 14 slices at 3.25 mm intervals. The rat (240-300 g) is anesthetized with 0.02% isoflurane throughout the PET study. The anesthetized rat is positioned prone on a stereotaxic head holder made of polymethyl methacrylate. An incision is made on the scalp to locate the bregma, which is positioned at the tenth slice from caudal. After a transmission scan to correct for photon attenuation, the [11C]KF21213 (N=3) (43–56 MBq/1.2-1.9 nmol/kg body weight) or [11C]KF18446 (N=3) (50-55 MBq/1.8-4.9 nmol/kg body weight) is injected through the tail vein, and the time sequential tomographic scanning is performed for 60 min (20 frames by 30 sec and 50 frames by 1 min). |
References: [1]. Wang WF, et al. Carbon-11-labeled KF21213: a highly selective ligand for mapping CNS adenosine A(2A) receptors with positron emission tomography. Nucl Med Biol. 2000 Aug;27(6):541-6. | |
KF21213 is a highly selective ligand for mapping CNS adenosine A2A receptors. KF21213 shows a high affinity for the adenosine A2A receptors (Ki=3.0 nM).
[11C]KF21213 as a PET ligand for mapping adenosine A2A receptors in the central nervous system (CNS). KF21213 shows a high affinity for the adenosine A2A receptors in vitro (Ki=3.0 nM) and a very low affinity for the A1 receptors (Ki>10,000 nM)[1].
The uptake of [11C]KF21213 by the striatum gradually increases for the first 15 min and then decreases. The uptake by the cortex and cerebellum is rapidly decreased after injection. Their levels are compatible with that in the blood. Consequently, the uptake ratios of striatum to cortex and striatum to cerebellum increases up to 8.6±1.6 and 10.5±2.1 (N=4), respectively, by 60 min. The striatal activity level of [11C]KF21213 is retained for the initial 5 min and then gradually decreased with time, whereas that of [11C]KF18446 rapidly decreases.The cerebellar activity of the two ligands rapidly decreases.The striatum-to-cerebellum uptake ratio for [11C]KF21213 gradually increases to 2.4 6 0.5 (N 5 3) by 50-60 min, whereas that for [11C]KF18446 increases for the first 10 min and remains constant (1.4±0.3, N=3, at 25-35 min)[1].
[1]. Wang WF, et al. Carbon-11-labeled KF21213: a highly selective ligand for mapping CNS adenosine A(2A) receptors with positron emission tomography. Nucl Med Biol. 2000 Aug;27(6):541-6.
| Cas No. | 155271-17-3 | SDF | |
| Canonical SMILES | O=C(N1C)N(C)C2=C(N(C)C(/C=C/C3=CC=C(OC)C(C)=C3C)=N2)C1=O | ||
| 分子式 | C19H22N4O3 | 分子量 | 354.4 |
| 溶解度 | Soluble in DMSO | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 2.8217 mL | 14.1084 mL | 28.2167 mL |
| 5 mM | 0.5643 mL | 2.8217 mL | 5.6433 mL |
| 10 mM | 0.2822 mL | 1.4108 mL | 2.8217 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。